DOI: 10.12890/2023_003914

RS3PE syndrome with subsequent PMR caused by long-term DPP-4 inhibitor use

Authors

  • Yuichi Takahashi Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
  • Gautam Deshpande Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
  • Yoshinori Kanai Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
  • Kwang-Seok Yang Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan
  • Toshio Naito Department of General Medicine, Juntendo University Faculty of Medicine, Tokyo, Japan

y-takaha@juntendo.ac.jp

Keywords

RS3PE syndrome, dipeptidyl peptidase (DPP-4i), side effect, polymyalgia rheumatica (PMR)

Abstract

Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome has been reported in patients treated with dipeptidyl peptidase-4 inhibitors (DPP-4i). We experienced a case of RS3PE syndrome in a 73-year-old man with a history of type 2 diabetes, who developed RS3PE as a side effect of vildagliptin. Further to this, the patient developed polymyalgia rheumatica (PMR), the first such case associated with long-term DPP-4i use.

View the entire article

Downloads

References

  1. Research and Markets. Dipeptide Peptidase 4 (DPP-4) Inhibitors Market - Growth, Trends, and Forecast (2019 - 2024). 2015 [cited 2019 Apr 20]. Available from: https://www.researchandmarkets.com/reports/4758263/dipeptide-peptidase-4-dpp-4-inhibitors
  2. McCarty DJ, O’Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 1985;254:2763–2767.
  3. Karmacharya P, Donato AA, Aryal MR, Ghimire S, Pathak R, Shah K, et al. RS3PE revisited: a systematic review and meta-analysis of 331 cases. Clin Exp Rheumatol 2016;34:404–15.
  4. Mainali NR, Schmidt TR, Alweis R, George DL. Novel development of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome due to insulin therapy. Am J Case Rep 2014;15:119–122.
  5. Oyama K, Taniguchi J-I, Goto R, Matsui K. Remitting seronegative symmetrical synovitis with pitting edema syndrome in individuals with type 2 diabetes mellitus or impaired glucose tolerance. Diabetes Res Clin Pract 2015;110:e5–e8.
  6. Naranjo CA, Busto U,Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239–245.
  7. Bird HA, Esselinckx W, Dixon AS, Mowat AG, Wood PH. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 1979;38:434–439.
  8. Dasgupta B, Cimmino MA, Maradit-Kremers H, Schmidt WA, Schirmer M, Salvarani C, et al. 2012 provisional classification criteria for polymyalgia rheumatica: a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Ann Rheum Dis 2012;71:484–492.
  9. Olivieri I, Salvarani C, Cantini F. RS3PE syndrome: an overview. Clin Exp Rheumatol 2000;18:S53–S55.
  10. Yamauchi K, Sato Y, Yamashita K, Funase Y, Kaneko T, Hashimoto T, et al. RS3PE in association with dipeptidyl peptidase-4 inhibitor: report of two cases. Diabetes Care 2012;35:e7.
  11. FDA Drug Safety Communication. Drug Safety and Availability. FDA Drug Safety Communication: FDA warns that DPP-4 inhibitors for type 2 diabetes may cause severe joint pain. 2015 [cited 2019 Apr 21]. Available from: https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-warns-dpp-4-inhibitors-type-2-diabetes-may-cause-severe-joint-pain
  12. Arima K, Origuchi T, Tamai M, Iwanaga N, Izumi Y, Huang M, et al. RS3PE syndrome presenting as vascular endothelial growth factor associated disorder. Ann Rheum Dis 2005;64:1653–1655.
  13. Fadini GP, Boscaro E, Albiero M, Menegazzo L, Frison V, de Kreutzenberg S, et al. The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. Diabetes Care 2010;33:1607–1609.

Published

2023-06-12

Issue

Vol. 10 No. 7 (2023)

Categories

How to Cite

1.
Takahashi Y, Deshpande G, Kanai Y, Yang K-S, Naito T. RS3PE syndrome with subsequent PMR caused by long-term DPP-4 inhibitor use. EJCRIM [Internet]. 2023 Jun. 12 [cited 2026 Nov. 3];10(7). Available from: https://ejcrim.com/index.php/ejcrim/article/view/3914